LNTH
Lantheus Holdings, Inc.Company Information
- Company Name
- Lantheus Holdings, Inc.
- CIK
- CIK0001521036
- Category
- Large accelerated filer
- Ticker: Exchange
- LNTH: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2835
- SIC Description
- In Vitro & In Vivo Diagnostic Substances
- Ticker
- LNTH
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- 2025-08-20
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 6,913,370
Institutional Sentiment
- As of
- 2026-03-31
- Institutional shares owned
- 68,944,801
- Shares outstanding
- 64,736,000
- Ownership
- 106.50%
Earnings Market Reaction
- Filing date
- 2026-08-06
- Price on filing date
- —
- 1-month reaction
- -0.30%
- 3-month reaction
- Pending
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 593 | 499 | 359 | 382 | 696 | 939 | 913 | 866 | 757 | 718 | 714 | 614 | ||||||
| Accounts Receivable Net Current | 353 | 356 | 359 | 351 | 337 | 349 | 321 | 329 | 372 | 337 | 284 | 259 | ||||||
| Inventory Net | 58 | 61 | 65 | 62 | 62 | 69 | 68 | 71 | 71 | 70 | 64 | 56 | ||||||
| Income Taxes Receivable | 1 | 1 | 15 | 32 | - | - | 8 | - | - | - | - | - | ||||||
| Other Assets Current | 22 | 25 | 21 | 21 | 34 | 67 | 16 | 22 | 24 | 16 | 17 | 11 | ||||||
| Assets Of Disposal Group Including Discontinued Operation Current | 0 | 0 | 81 | 77 | 73 | - | 0 | 7 | 7 | 7 | 7 | 7 | ||||||
| Assets Current | 1,027 | 942 | 900 | 925 | 1,202 | 1,424 | 1,327 | 1,296 | 1,231 | 1,149 | 1,086 | 948 | ||||||
| Equity Securities Fv Ni And Without Readily Determinable Fair Value | 119 | 58 | 42 | 46 | 45 | 30 | 39 | 159 | 116 | 139 | 0 | - | ||||||
| Notes And Loans Receivable Net Noncurrent | 25 | 92 | - | - | - | - | - | - | - | - | - | - | ||||||
| Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization | 153 | 158 | 164 | 164 | 158 | 181 | 177 | 170 | 158 | 150 | 147 | 140 | ||||||
| Intangible Assets Net Excluding Goodwill | 689 | 706 | 723 | 739 | 360 | 154 | 162 | 174 | 172 | 142 | 152 | 163 | ||||||
| Goodwill | 239 | 239 | 240 | 240 | 177 | 61 | 61 | 61 | 61 | 61 | 61 | 61 | ||||||
| Deferred Income Tax Assets Net | 103 | 89 | 109 | 107 | 138 | 169 | 170 | 145 | 151 | 139 | 150 | 152 | ||||||
| Other Assets Noncurrent | 60 | 62 | 50 | 54 | 36 | 36 | 44 | 46 | 49 | 51 | 55 | 56 | ||||||
| Assets | 2,415 | 2,347 | 2,227 | 2,276 | 2,116 | 2,055 | 1,980 | 2,050 | 1,940 | 1,831 | 1,651 | 1,522 | ||||||
Liabilities Current | ||||||||||||||||||
| Long Term Debt Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 565 | 1 | 1 | 1 | 1 | ||||||
| Accounts Payable Current | 48 | 46 | 43 | 66 | 41 | 45 | 35 | 45 | 50 | 38 | 41 | 37 | ||||||
| Business Combination Contingent Consideration Liability Current | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Accounts Payable And Other Accrued Liabilities Current | 287 | 286 | 267 | 251 | 209 | 202 | 205 | 174 | 213 | 199 | 145 | 139 | ||||||
| Liabilities Of Disposal Group Including Discontinued Operation Current | 0 | 0 | 22 | 29 | 30 | - | 0 | - | - | - | - | - | ||||||
| Liabilities Current | 336 | 333 | 333 | 347 | 280 | 248 | 241 | 784 | 263 | 237 | 187 | 177 | ||||||
| Asset Retirement Obligations Noncurrent | 0 | 0 | 0 | 0 | 0 | 19 | 23 | 23 | 23 | 23 | 23 | 23 | ||||||
| Long Term Debt And Capital Lease Obligations | 570 | 570 | 569 | 568 | 567 | 566 | 565 | 1 | 563 | 562 | 562 | 561 | ||||||
| Deferred Income Tax Liabilities Net | 54 | 54 | 54 | 55 | - | - | 0 | - | - | - | - | - | ||||||
| Business Combination Contingent Consideration Liability Noncurrent | 51 | 73 | 73 | 71 | - | - | 0 | - | - | - | - | - | ||||||
| Other Liabilities Noncurrent | 92 | 105 | 108 | 116 | 102 | 58 | 63 | 62 | 64 | 63 | 63 | 63 | ||||||
| Liabilities | 1,103 | 1,134 | 1,138 | 1,157 | 949 | 891 | 892 | 870 | 913 | 886 | 835 | 823 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Additional Paid In Capital Common Stock | 918 | 893 | 888 | 871 | 845 | 821 | 818 | 797 | 776 | 756 | 758 | 744 | ||||||
| Treasury Stock Common Value | -477 | -477 | -477 | -376 | -275 | -175 | -175 | -75 | -75 | -75 | -75 | -75 | ||||||
| Retained Earnings Accumulated Deficit | 873 | 798 | 680 | 625 | 598 | 519 | 446 | 458 | 327 | 265 | 134 | 30 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -2 | -2 | -1 | -2 | -1 | -2 | -2 | -1 | -1 | -1 | -1 | -1 | ||||||
| Stockholders Equity | 1,312 | 1,212 | 1,090 | 1,119 | 1,167 | 1,164 | 1,088 | 1,180 | 1,027 | 946 | 816 | 699 | ||||||
| Liabilities And Stockholders Equity | 2,415 | 2,347 | 2,227 | 2,276 | 2,116 | 2,055 | 1,980 | 2,050 | 1,940 | 1,831 | 1,651 | 1,522 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | ||||||
| Preferred Stock Shares Authorized | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | ||||||
| Common Stock Shares Authorized | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | ||||||
| Common Stock Shares Issued | 73 | 72 | 72 | 72 | 72 | 72 | 71 | 71 | 71 | 71 | 70 | 70 | ||||||
| Shares Outstanding | 65 | 65 | 65 | 72 | 72 | 72 | 68 | 71 | 71 | 71 | 70 | 70 | ||||||
| Treasury Stock Common Shares | 7 | 7 | 7 | 5 | 4 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialLantheus Holdings, Inc. (LNTH) — SEC Financial Statements & Analysis
Lantheus Holdings, Inc. (LNTH) is a in vitro & in vivo diagnostic substances company, incorporated in DE. Lantheus Holdings, Inc. trades on Nasdaq as: LNTH. Lantheus Holdings, Inc. (LNTH)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, Lantheus Holdings, Inc. carries a market cap of $7.23B, a P/E ratio of 26.26x, a P/B ratio of 5.51x, a P/S ratio of 4.64x, an enterprise value of $7.21B, and an EV/EBITDA multiple of 18.44x. On profitability, it posts a gross margin of 60.14%, an operating margin of 19.43%, a net margin of 17.69%, a Return on Equity (ROE) of 22.21%, a Return on Assets (ROA) of 12.15%, and a Return on Invested Capital (ROIC) of 19.20%. Per share, it reports EPS of $4.23, diluted EPS of $4.08, free cash flow per share of $5.95, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 2.35% year-over-year, net income growth of 1.59% year-over-year, and EPS growth of 6.82% year-over-year. On the balance sheet, it maintains a current ratio of 3.06x, a quick ratio of 2.89x, working capital of $691.38M, a debt-to-equity ratio of 0.84x, a debt ratio of 0.46, an interest coverage ratio of 15.26x, free cash flow of $387.83M (TTM), and net debt of $-22.25M. Figures sourced from SEC EDGAR.
- Market Cap
- $7.23B
- P/E TTM
- 26.26x
- EPS TTM
- $4.23
- P/B TTM
- 5.51x
- ROE TTM
- 22.21%
- ROA TTM
- 12.15%
- Debt To Equity
- 0.84x
- Free Cash Flow TTM
- $387.83M
- Net Revenue TTM Growth 1Y
- 2.35%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Lantheus Holdings, Inc. in?
Lantheus Holdings, Inc. (LNTH) operates in the In Vitro & In Vivo Diagnostic Substances industry.
What exchange does LNTH trade on?
Lantheus Holdings, Inc. (LNTH) trades on the Nasdaq.
Where is Lantheus Holdings, Inc. incorporated?
Lantheus Holdings, Inc. is incorporated in DE.
When was Lantheus Holdings, Inc. (LNTH)'s most recent SEC filing?
Lantheus Holdings, Inc. (LNTH)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06.
What is LNTH's market cap?
Lantheus Holdings, Inc. (LNTH) has a market capitalization of $7.23B as of 2026-06-30.
What is LNTH's P/E ratio?
Lantheus Holdings, Inc. (LNTH)'s trailing twelve month P/E ratio is 26.26x as of 2026-06-30.
What is LNTH's EPS (earnings per share)?
Lantheus Holdings, Inc. (LNTH)'s trailing twelve month EPS is $4.23 as of 2026-06-30.
What is LNTH's ROE (return on equity)?
Lantheus Holdings, Inc. (LNTH)'s trailing twelve month Return on Equity (ROE) is 22.21% as of 2026-06-30.
What is LNTH's ROA (return on assets)?
Lantheus Holdings, Inc. (LNTH)'s trailing twelve month Return on Assets (ROA) is 12.15% as of 2026-06-30.
What is LNTH's ROIC (return on invested capital)?
Lantheus Holdings, Inc. (LNTH)'s trailing twelve month Return on Invested Capital (ROIC) is 19.20% as of 2026-06-30.
What is LNTH's EV/EBITDA?
Lantheus Holdings, Inc. (LNTH)'s trailing twelve month EV/EBITDA is 18.44x as of 2026-06-30.